Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T15:17:20.223Z.
Consensus retrieved: unavailable. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T15:17:20.223Z.
Quote observation: 2026-10-06T14:41:12.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 758569c9a5200ff865148ece812cfee1584848efe17be54014067a65be913c54
FORWARD PE RATIO
N/A
InterCure Ltd.
Market Cap
$64.68M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| InterCure Ltd. (INCR) | $64.68M | N/A |
| Heron Therapeutics, Inc. (HRTX)vs › | $65.11M | N/A |
| Cingulate Inc. (CING)vs › | $65.73M | N/A |
| Gossamer Bio, Inc. (GOSS)vs › | $65.81M | N/A |
| Kalaris Therapeutics Inc (KLRS)vs › | $63.30M | N/A |
| Alps Group Inc (ALPS)vs › | $63.23M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $61.52M | N/A |
| Champions Oncology, Inc. (CSBR)vs › | $68.08M | 49.00 |
| Adicet Bio, Inc. (ACET)vs › | $60.95M | N/A |
| Fortress Biotech, Inc. (FBIO)vs › | $68.43M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus fiscal-year EPS
Consensus estimates for this stock are reported in ILS, while the share price trades in USD — so per-fiscal-year implied multiples can't be computed honestly here. The analyst estimates table shows the consensus figures with their correct currency label.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
